ReviewMaterials today. Bio2025
Recent advances in copper sulfide nanoparticles for cancer diagnosis and therapy.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Nano-hydrogel-based delivery system for dihydroartemisinin to enhance cuproptosis and synergize with anti-PD-1 therapy in triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
- A precise theranostic nanoplatform amplifies anti-tumor efficacy via copper ionophores and sonodynamic therapy.Materials today. Bio · 2026Article
- Review
- Engineering Biocompatible Glutathione-Capped CuMaterials (Basel, Switzerland) · 2026Article
- Novel Synergistic Strategy for Enhanced Performance in NIR-II FI-PAI-MRI Trimodal Imaging.ACS omega · 2026Article
- A nomogram integrating CTPA parameters and serum biomarkers to predict 30-day mortality and refine risk stratification in non-high-risk acute pulmonary embolism.Frontiers in cardiovascular medicine · 2026Article
- Advances in Versatile Copper Sulfide-Based Nanoplatforms: From Synthesis and Properties to Multifaceted Biomedical Applications.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer, a highly heterogeneous and complex disease characterized by multiple genetic and metabolic abnormalities, remains one of the leading causes of death worldwide. Although conventional treatments such as surgery, chemotherapy, and radiotherapy, can mitigate the disease to some extent, their efficacy remains constrained by various factors. In recent years, nanotechnology has emerged as a promising approach for cancer treatment, with copper-based nanomaterials garnering significant attention due to their unique physicochemical properties and favorable biocompatibility. Copper sulfide (CuS) nanomaterials, in particular, have shown great potential as a versatile platform for both diagnosis and therapy, primarily due to their superior photothermal properties. Moreover, copper plays a crucial role in tumorigenesis, progression, and multiple cell death pathways, further highlighting its potential in cancer therapy. This review discusses the metabolic regulation of copper and its diverse roles in tumor biology, examines the applications and recent advances of CuS nanomaterials in cancer therapy, and explores their future potential in cancer diagnosis and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.